We are live on ! Find out more
TCRR

TCR2 Therapeutics Inc. Common Stock
TCRR

Delisted

TCRR was delisted on the 31st of May, 2023.

Back to rankings

122 hedge funds and large institutions have $136M invested in TCR2 Therapeutics Inc. Common Stock in 2021 Q4 according to their latest regulatory filings, with 40 funds opening new positions, 34 increasing their positions, 35 reducing their positions, and 32 closing their positions.

New
Increased
Maintained
Reduced
Closed

25% more first-time investments, than exits

New positions opened: 40 | Existing positions closed: 32

4% more funds holding

Funds holding: 117 → 122 (+5)

0% more funds holding in top 10

Funds holding in top 10: 2 → 2 (0)

3% less repeat investments, than reductions

Existing positions increased: 34 | Existing positions reduced: 35

50% less capital invested

Capital invested by funds: $270M → $136M (-$134M)

57% less call options, than puts

Call options by funds: $123K | Put options by funds: $288K

Holders
122
Holders Change
+5
Holders Change %
+4.27%
% of All Funds
1.88%
Holding in Top 10
2
Holding in Top 10 Change
–
Holding in Top 10 Change %
–
% of All Funds
0.03%
New
40
Increased
34
Reduced
35
Closed
32
Calls
$123K
Puts
$288K
Net Calls
-$165K
Net Calls Change
+$2.67M

Top Buyers

Rank Fund Capital Flow
1
Millennium Management
Millennium Management
New York
+$7.23M
2
Bank of America
Bank of America
North Carolina
+$7.08M
3
Renaissance Technologies
Renaissance Technologies
New York
+$4.36M
4
BBA
Baker Bros. Advisors
New York
+$3.6M
5
D.E. Shaw & Co
D.E. Shaw & Co
New York
+$2.77M

Top Sellers

Rank Fund Capital Flow
1
RG
Redmile Group
California
-$15.4M
2
Wellington Management Group
Wellington Management Group
Massachusetts
-$11.9M
3
State Street
State Street
Massachusetts
-$6.25M
4
FLAM
First Light Asset Management
Minnesota
-$5.28M
5
ACH
ArrowMark Colorado Holdings
Colorado
-$4.91M
Name Holding Trade Value Shares
Change 		Change in
Stake
Jacobs Levy Equity Management
26
Jacobs Levy Equity Management
New Jersey
$952K +$1.28M +204,290 New
Walleye Capital
27
Walleye Capital
New York
$949K +$602K +96,356 +90%
TI
28
Trexquant Investment
Connecticut
$798K +$515K +82,396 +93%
HF
29
HRT Financial
New York
$760K +$957K +153,013 +1,517%
PP
30
PDT Partners
New York
$741K +$835K +133,532 +525%
AA
31
AlphaCentric Advisors
Puerto Rico
$704K +$238K +38,000 +34%
OQS
32
Occudo Quantitative Strategies
Florida
$643K +$862K +137,951 New
BNP Paribas Financial Markets
33
BNP Paribas Financial Markets
France
$615K +$776K +124,064 +1,584%
Nomura Holdings
34
Nomura Holdings
Japan
$604K +$806K +128,977 New
Dimensional Fund Advisors
35
Dimensional Fund Advisors
Texas
$590K -$66.6K -10,647 -8%
Bank of New York Mellon
36
Bank of New York Mellon
New York
$519K +$25.1K +4,021 +4%
N
37
Nuveen
North Carolina
$511K -$65.1K -10,419 -9%
AFM
38
Anson Funds Management
Texas
$475K +$637K +101,839 New
AIMCA
39
Alberta Investment Management Corp (AIMCo)
Alberta, Canada
$466K +$625K +100,000 New
CSS
40
Cubist Systematic Strategies
Connecticut
$460K +$201K +32,078 +48%
Victory Capital Management
41
Victory Capital Management
Texas
$393K -$81.3K -13,006 -13%
HCA
42
Harbor Capital Advisors
Illinois
$390K +$523K +83,619 New
Susquehanna International Group
43
Susquehanna International Group
Pennsylvania
$361K +$307K +49,155 +173%
GCP
44
GSA Capital Partners
United Kingdom
$347K +$5.14K +823 +1%
Marshall Wace
45
Marshall Wace
United Kingdom
$320K -$744K -118,940 -63%
AQR Capital Management
46
AQR Capital Management
Connecticut
$304K +$408K +65,220 New
Jane Street
47
Jane Street
New York
$294K +$325K +51,949 +464%
DTL
48
Dynamic Technology Lab
Singapore
$272K +$233K +37,288 +178%
JF
49
Jump Financial
Illinois
$254K +$341K +54,500 New
MAM
50
Martingale Asset Management
Massachusetts
$244K +$327K +52,234 New
1
2
3 4 5

TCRR Hedge Fund Activity: Q4 2021 in Review

122 of the 6,499 institutional investors tracked by Wall St. Rank reported a position in TCR2 Therapeutics Inc. Common Stock (TCRR) for Q4 2021, worth a combined $136M — down 50% from $270M a quarter earlier.

Buyers outnumbered sellers: 40 funds opened new TCRR positions and 32 closed out — a net gain of 8 holders — while 34 added to existing stakes and 35 trimmed.

The largest buyer was Millennium Management, adding an estimated $7.23M. The largest seller was Redmile Group, cutting an estimated $15.4M.

  • 122 institutional investors held TCR2 Therapeutics Inc. Common Stock (TCRR) as of Q4 2021, up from 117 in Q3 2021.
  • Funds reported $136M of TCR2 Therapeutics Inc. Common Stock stock for Q4 2021, down 50% quarter-over-quarter.
  • 40 funds opened new TCR2 Therapeutics Inc. Common Stock positions in Q4 2021 and 32 closed out, a net change of +8 holders.
  • The largest TCR2 Therapeutics Inc. Common Stock buyer in Q4 2021 was Millennium Management, an estimated $7.23M added.
  • The largest TCR2 Therapeutics Inc. Common Stock seller in Q4 2021 was Redmile Group, an estimated $15.4M sold.

Based on aggregated 13F filings for Q4 2021.